AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02131740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye rubbing
Description: eye rubbing for 1 minute in horizontal direction clockwise, 5 second rest \& eye rubbing for a further 1 minute.
Study NCT02131740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No eye rubbing
Description: This eye will not be rubbed
Study NCT04357418 — intervention group
Intervention type: OTHER
Intervention: it is a survey
Description: this interview can be carried out face to face or remotely.
Study NCT04506827 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Sinus Augmentation
Description: Biomaterial Graft into the Maxillary Sinus
Study NCT01201187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-162
Description: YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
Study NCT01201187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1T/twice a day(bid) for 8weeks, po medication
Study NCT04506827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary Sinus Augmentation
Description: Biomaterial Graft into the Maxillary Sinus
Study NCT04506827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Sinus Graft with ABBM
Description: The maxillary sinuses in the control group are grafted with ABBM
Study NCT04506827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary Sinus Graft with TCP
Description: The maxillary sinuses in the test1 group are grafted with TCP
Study NCT04506827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary Sinus Graft with TCP + HA
Description: The maxillary sinuses in the test1 group are grafted with TCP + HA
Study NCT02100748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130
Description: TRV130 1 - 4 mg will be administered every 4 hours
Study NCT02100748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine 4 mg will be administered every 4 hours
Study NCT02100748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered every 4 hours
Study NCT00745485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Study NCT03636776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life in metastatic BC
Description: 1 month after metastatic stage diagnosis, patients complete their 1st therapeutic sequence evaluation visit (T1) within the recommended standard time frames. If the disease remains stable or if a response to treatment is observed then patients continue their follow-up in the same therapeutic sequence (T1).~If progression occurs, treatment is modified and patients move on to the next therapeutic sequence (T2).~And so on as many times as necessary. Before each evaluation visit with investigator, patients complete the questionnaires QLQ-C30, BR23, STAI, BDI II
Study NCT00398684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose nevirapine to the mother and to the child
Description: One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
Study NCT00398684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose nevirapine to the mother and placebo to the child
Description: One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
Study NCT00398684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single dose placebo to the mother and to the child
Description: One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
Study NCT00898768 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capsule endoscopy
Description: Capsule endoscopy at baseline and after 2 years
Study NCT03230123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green banana biomass
Description: Green banana biomass will be suplemented to diet as 4.5 g per day.
Study NCT03230123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green banana biomass
Description: Green banana biomass will be suplemented to diet as 4.5 g per day.
Study NCT00869440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNS 7056
Description: Administered as a single intravenous injection by a syringe driver over 1 minute
Study NCT00869440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered as a single intravenous injection by a syringe driver over 1 minute
Study NCT03304431 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Orotracheal Lidocaine Oral Spray application
Description: The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
Study NCT04629274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: The patients will be asked to provide at least 2 peripheral blood samples of approximately 100 milliliters each time, with a minimum of 14 days interval between these 2 samples.If the results obtained with the 2 initial samples would be of interest to the Sponsor, the patient will be asked to come back for additional samplings with a maximum of 6 additional blood draws
Study NCT01923311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVG
Description: Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily
Study NCT04009174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Panel
Description: Initial Protocol (REB approval date 08-Sept-2011)~Pre-operative Imaging Panel~* \[18F\]-FCH PET + Dynamic CT~* MRI of the pelvis with endorectal coil (T1, T2, DW, DCE, MRS)~* 3D-Transrectal ultrasound~* Optional PET/MRI (added with Protocol Amend 1, REB approval date 22-Aug-2012)~* Optional Sodium (23Na) MRI (added with Protocol Amend 2, REB approval date 25-Feb-2013)~Protocol Amendment #3, REB approval date 20-Oct-2015:~Pre-operative Imaging Panel~* \[18-F\]-DCFPyL PET+Dynamic CT~* PET/MRI with endorectal coil~* 3D-Transrectal Ultrasound~* Optional Sodium (23Na) MRI
Study NCT02405052 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Validation of the Panic Screening Score
Study NCT04511637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form
Description: 15 mg as 1 x 15 mg orally disintegrating tablet (ODT)
Study NCT04511637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Description: 15 mg as 1 x 15 mg film-coated tablet
Study NCT01923311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background regimen
Description: Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants \< 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
Study NCT04305990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Demand-driven delivery method
Description: The gas delivery device is set to the demand-driven setting. Patients must inspire through their nose to trigger the flow of gas.
Study NCT04305990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free-flow delivery method
Description: The gas delivery device is set to a free-flow setting. Gas flows through the system at a rate determined by the operator. Standard flow rate is 6 liters per minute. Patients do not need to inspire through their nose to trigger the flow of gas.
Study NCT03969901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMI/REL
Description: Age-based dosing:~* 12 to \<18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours~* 2 to \<12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* 3 months to \<2 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* Birth to \<3 month, IMI 15 and REL 7.5 mg/kg, IV infusion every 8 hours NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention.
Study NCT03398044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered to patients randomised into the active treatment arm, in order to determine the influence upon PONV incidence.
Study NCT03398044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to patients randomised into the control group arm.
Study NCT03969901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.~NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents.
Study NCT00321984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
Study NCT00321984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
Study NCT00321984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
Study NCT03640806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHYSICAL ACTIVITY
Description: 3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
Study NCT00138151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alpha-2b
Description: Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
Study NCT00138151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
Study NCT00138151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
Study NCT01593683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological education program for nurses
Description: Approximately 4 weekly one-hour group sessions led by study clinicians and 1 optional individual session with a single study clinician.
Study NCT02580916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCQOLIT questionnaire
Description: Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires \[Appendices C \& D) at:~1. baseline (after histological diagnosis of a NMSC is confirmed - both Groups)~2. 3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up~3. at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)
Study NCT02936323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-221
Description: PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose of 1 mg with each subsequent cohort increased starting dose level until MTD is reached.
Study NCT02936323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-221
Description: PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose at recommended Phase 2a dose established in Phase 1.
Study NCT03960814 — intervention group
Intervention type: DRUG
Intervention: Insulin detemir
Description: No treatment will be given to the patients in relation to this study. Patients have been included in this study because they have been treated with insulin glargine or detemir prior to study initiation (2004 - 2018) and according to routine clinical practice at that time. The decision to initiate treatment with commercially available insulin detemir and glargine has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Study NCT00306189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg AMG 162
Description: 100 mg AMG 162 (denosumab) SC every 6 months
Study NCT00306189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60 mg AMG 162
Description: 60 mg AMG 162 (denosumab) SC every 6 months
Study NCT00306189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14 mg AMG 162
Description: 14 mg AMG 162 (denosumab) SC every 6 months
Study NCT00306189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC every 6 months
Study NCT01088750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT01088750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Study NCT01088750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate
Study NCT01088750 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: watchful waiting
Study NCT01088750 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery
Study NCT02044445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oocyte retrieval will be performed 36 h or 38 h after hCG administration
Description: Oocyte retrieval will be performed 36 h or 38 h after hCG administration
Study NCT01403311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevuline Acid
Description: 5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
Study NCT02421471 — intervention group
Intervention type: DRUG
Intervention: Ingenol mebutate 0.015 percent or 0.05 percent gel
Description: Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
Study NCT02083965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: Administered as specified in the treatment arm.
Study NCT03363997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol 0.125 mg/day
Description: Application of one vaginal ring
Study NCT03363997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol 0.250 mg/day
Description: Application of one vaginal ring
Study NCT03363997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol 0.500 mg/day
Description: Application of one vaginal ring
Study NCT00354861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B antigen (without alum) plus IMP321
Description: hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321
Study NCT00354861 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: hepatitis B antigen alone (without alum)
Description: hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline
Study NCT00354861 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: 20 µg hepatitis B antigen absorbed on alum
Study NCT01275820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutralin
Description: Food product to be taken 15 minutes prior to each of the three main meals of the day.
Study NCT04346082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online mindfulness group
Description: Each weekly mindfulness session will last 45 to 60 minutes and will be held on an online platform (e.g. Zoom) via a livestream video. It will consist of short mindfulness exercise(s) of 10-30 minutes, including mindful tasting, mindful stretching, mindful walking, and body scan followed by group discussion to share, explore and make sense of the meditative experience. The intervention will be held in Cantonese.
Study NCT00293033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEMA™
Description: BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
Study NCT00293033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BEMA™
Description: BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
Study NCT00293033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03118713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: oral
Study NCT03118713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral
Study NCT03118713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: oral
Study NCT03950011 — intervention group
Intervention type: PROCEDURE
Intervention: Enhanced recovery after surgery program
Description: Enhanced Recovery After Surgery Programs (ERP) includes multimodal approaches of perioperative patient's clinical pathways designed to achieve early recovery after surgery and a decreased length of hospital stay (LOS).
Study NCT00607815 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: CPT is a highly structured protocol in which the client learns the skill of recognizing and challenging dysfunctional cognitions, first about the worst traumatic event and then later with regard to the meaning of the events for current beliefs about self and others.
Study NCT00607815 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: Present centered therapy is a supportive counseling model developed by Drs. Foa and Shea. The treatment is called present centered therapy to 1) emphasize the need to focus on the participant's current life and 2) to conceptualize the problems as being caused by PTSD, and in some cases they may have been present for a long period of time. The treatment makes a connection between PTSD and current problems thus making it a more realistic PTSD treatment and still allowing PCT to control for nonspecific therapeutic factors
Study NCT00482027 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC09
Description: one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
Study NCT01817244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care management
Description: 6-month care management
Study NCT01817244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: care management
Description: 6-month care management
Study NCT01640587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine+Artesunate
Description: One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2
Study NCT01640587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
Study NCT04686006 — intervention group
Intervention type: DRUG
Intervention: Potassium Iodide
Study NCT04310657 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mNGS
Description: Metagenomics second generation sequencing technology
Study NCT03131193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician
Description: Study primary health centers will be staffed with an additional physician
Study NCT03131193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mid-level provider
Description: Study primary health centers will be staffed with an additional mid-level provider
Study NCT03131193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer
Description: Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant